flow cytometry

2:11
Targeted RNA-sequencing for the quantification of MRD in AML
Christopher Hourigan
1:27
MRD detection for AML in China & MFC to detect CEPBA mutations
Hong-Hu Zhu
1:51
Predicting IMiD sensitivity in myeloma
Rafael Fonseca
1:36
Future biomarkers for MDS
Alan List
2:24
Better together? Ibrutinib and venetoclax for high-risk CLL
Nitin Jain
2:36
iFCG for the frontline treatment of IGHV-mutated CLL: trial update
Nitin Jain
4:47
Role of persistent MRD in MM and elderly AML using next-generation flow
Bruno Paiva
1:33
Characterization of the immune impact of daratumumab by mass cytometry in multiple myeloma
Gareth Morgan
2:11
Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s
Jonas Paludo
3:23
The definitive guide to multiple myeloma at ASH 2018: part III
Mohamad Mohty et al.
3:42
MRD detection in myeloma autografts: 8-colour flow cytometry or NGS?
Hiroyuki Takamatsu
1:28
Flow cytometry vs. NGS testing for determining MRD negativity in patients with ALL
Stephan Grupp
2:06
Identifying relapse in B-ALL patients treated with tisagenlecleucel using MRD
Stephan Grupp
1:11
Let me introduce you to ERIC: the European Research Initiative on CLL
Paolo Ghia
2:34
MRD in CLL: utility from trials to individuals
John Seymour
1:59
The expanding role of MRD in CLL
Florence Cymbalista
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals